- JP-listed companies
- Oncolys BioPharma Inc.
- Income statement
Oncolys BioPharma Inc.【JP:4588】Income statement
Market cap
¥57.6B
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 186 | 397 | 1 | 29 | 121 | 178 | 229 | 169 | 1,304 | 314 | 642 | 976 | 63 | 31 | 29 |
| Revenue growth (%) | - | ||||||||||||||
| Gross profit | - | - | - | 28 | 121 | 178 | 158 | 47 | 1,191 | 236 | 199 | 338 | 31 | 31 | 29 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 856 | 1,073 | 1,040 | 1,236 | 1,295 | 1,702 | 1,911 | 1,653 | 1,543 | 1,961 | 1,713 | 2,053 |
| Operating income | - | - | - | -828 | -952 | -861 | -1,078 | -1,248 | -511 | -1,675 | -1,455 | -1,205 | -1,930 | -1,681 | -2,024 |
| Income before tax | -6 | -99 | -625 | -726 | -855 | -864 | -1,087 | -1,230 | -539 | -1,724 | -1,501 | -1,163 | -1,914 | -1,664 | -2,051 |
| Pretax margin (%) | -3.1 | -24.9 | -52,991.7 | -2,521.4 | -704.6 | -484.7 | -474.5 | -729.8 | -41.4 | -548.6 | -233.6 | -119.1 | -3,036 | -5,301.8 | -7,184.9 |
| Provision for income taxes | - | - | - | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 4 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | 15 | -103 | -636 | -739 | -857 | -931 | -1,091 | -1,234 | -912 | -2,095 | -1,615 | -1,149 | -1,939 | -1,685 | -2,058 |
| Net income margin (%) | |||||||||||||||
| Earnings per share | 2.97 | -16.83 | -94.33 | -80.55 | -93.35 | -101.18 | -106.23 | -104.55 | -65.55 | -145.58 | -95.5 | -66.31 | -108.92 | -77.17 | -80 |
| Diluted EPS | 2.77 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | ||||||||||||
| EBITDA margin (%) | - | - | - |